Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05321407 · ClinicalTrials.gov registry record

COVID-19 Vaccine Responses in PIDD Subjects

A clinical trial of Common Variable Immunodeficiency and Primary Immune Deficiency, sponsored by Duke University.

Active
Registry status
100
Enrollment target
3
Study locations

NCT05321407 is a study of Common Variable Immunodeficiency and Primary Immune Deficiency that is active but no longer recruiting, run by Duke University. The registered enrollment target is 100 participants, below the 215-participant average among 7 other Common Variable Immunodeficiency trials with a reported enrollment target (53% lower). The trial reports 3 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05321407, a study of Common Variable Immunodeficiency and Primary Immune Deficiency, is active but no longer recruiting, sponsored by Duke University.

ACTIVE NOT RECRUITING
Registry status
100 participants
Enrollment target
3
Study locations

Study Summary

The goal of our study is to assess the cellular immune responses of participants with antibody deficiency disease before and after immunization with SARS-CoV-2 mRNA vaccines.

Study Locations (3)

North Carolina

  • University of North Carolina, Chapel Hill - Chapel Hill
  • Duke University - Durham

Florida

  • University of South Florida - St. Petersburg

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2021-09-30
Est. Completion 2026-07-31

Sponsor

Duke University

1,725 total trials

What the Registry Record Tells You About NCT05321407

The ClinicalTrials.gov registry entry for NCT05321407 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 215-participant average among 7 other Common Variable Immunodeficiency trials with a reported enrollment target (53% lower). The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.

The record links to 7 conditions, with Common Variable Immunodeficiency appearing as the primary indexed condition, and to 0 interventions.

NCT05321407 reports 3 study locations spanning 2 distinct geographic areas - top geographies include North Carolina, Florida.

Frequently Asked Questions

What is clinical trial NCT05321407 about?

NCT05321407 is a clinical study titled "COVID-19 Vaccine Responses in PIDD Subjects". The goal of our study is to assess the cellular immune responses of participants with antibody deficiency disease before and after immunization with SARS-CoV-2 mRNA vaccines.

What is the current status of trial NCT05321407?

This trial is currently active not recruiting. The enrollment target is 100 participants. The study started on 2021-09-30. Estimated completion is 2026-07-31.

What conditions does trial NCT05321407 study?

This clinical trial studies the following conditions: Common Variable Immunodeficiency, Primary Immune Deficiency, CVID, XLA, X-linked Agammaglobulinemia.

Who is sponsoring clinical trial NCT05321407?

This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05321407 being conducted?

This trial has 3 study locations across Florida, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Common Variable Immunodeficiency

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.